Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Pharmacological Study

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT00079131Phase 2Completed

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Showing all 1 trials

Research Network

Common Treatments

  • Pharmacological Study1
  • Laboratory Biomarker Analysis1
  • Oblimersen Sodium1

Active Sponsors

  • National Cancer Institute (NCI)1

Top Investigators

  • Ki Chung1

    Memorial Sloan Kettering Cancer Center

Related Conditions

  • Stage Iv Neuroendocrine Carcinoma Of The Skin1
  • Recurrent Neuroendocrine Carcinoma Of The Skin1
  • Stage Ii Neuroendocrine Carcinoma Of The Skin1
  • Stage Iii Neuroendocrine Carcinoma Of The Skin1

Activity Timeline